{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:34:01Z","timestamp":1778733241053,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ejca.2013.04.029","type":"journal-article","created":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T11:55:03Z","timestamp":1370001303000},"page":"2869-2876","source":"Crossref","is-referenced-by-count":125,"title":["A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid\u00ae) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"nct00655668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01553786","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Franck","family":"Morschhauser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Fitoussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Glaisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Gabarre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Bosly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.04.029_b0005","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d\u2019Etude des Lymphomes Agressives)","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2010.08298.x","article-title":"Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma","volume":"150","author":"d\u2019Amore","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2013.04.029_b0025","first-page":"1513","article-title":"Pentostatin in T-non-Hodgkin\u2019s lymphomas: efficacy and effect on CD26+ T lymphocytes","volume":"10","author":"Dang","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2013.04.029_b0030","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2013.04.029_b0035","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.04.029_b0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1016\/j.ejca.2013.04.029_b0045","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.04.029_b0050","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2010.08376.x","article-title":"Lenalidomide-induced tumour flare reaction in mantle cell lymphoma","volume":"151","author":"Eve","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2013.04.029_b0055","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.04.029_b0060","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.04.029_b0065","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0070","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0075","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.920.920","article-title":"Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma","volume":"114","author":"Pohlman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.04.029_b0080","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0085","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0090","article-title":"Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment","author":"Qi","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2013.04.029_b0095","article-title":"Lenalidomide (Revlimid\u00ae) in patients with cutaneous T-cell lymphoma","volume":"3","author":"Querfeld","year":"2009","journal-title":"Hematol Meet Rep"},{"key":"10.1016\/j.ejca.2013.04.029_b0100","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2011.572265","article-title":"Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma","volume":"52","author":"Querfeld","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2013.04.029_b0105","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.04.029_b0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2013.04.029_b0115","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2013.04.029_b0120","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.ejca.2013.04.029_b0125","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0130","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0135","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2013.04.029_b0140","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.04.029_b0145","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2013.04.029_b0150","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913003638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913003638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T12:48:21Z","timestamp":1715431701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913003638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0959804913003638"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.04.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}